Research To Practice | Oncology Videos

Latest Episodes:

Menin Inhibitors in Acute Myeloid Leukemia | Eunice S Wang, MD Apr 20, 2026

Show notes

Year in Review: Clinical Investigator Perspectives on the Most Relevant New Datasets and Advances in Menin Inhibitors in Acute Myeloid Leukemia | Faculty Presentation 1: Biology Underlying the Utility of Menin Inhibitors in Acute Leukemias: Use of These Agents as Monotherapy — Eunice S Wang, MD

CME information and select publications

Menin Inhibitors in Acute Myeloid Leukemia | Amir Fathi, MD Apr 20, 2026

Show notes

Year in Review: Clinical Investigator Perspectives on the Most Relevant New Datasets and Advances in Menin Inhibitors in Acute Myeloid Leukemia | Faculty Presentation 2: Potential Role of Menin Inhibitors as a Component of Combination Therapy — Amir Fathi, MD

CME information and select publications

Lung Cancer — 5-Minute Journal Club with Dr Natalie Vokes: Current and Future Role of Tumor-Informed Circulating Tumor DNA Assays Apr 17, 2026

Show notes

Featuring an interview with Dr Natalie Vokes, including the following topics:

Perioperative minimal residual disease (MRD) detected by circulating tumor DNA (ctDNA) testing in patients with lung cancer (0:00)
- Ohara S et al. Clinical significance of perioperative MRD detected by ctDNA in patients with lung cancer with a long follow-up data: An exploratory study. JTO Clin Res Rep 2024;6(3):100762. Abstract
- Masuda K et al. MRDSEEKER (JCOG2111A): A prospective study to evaluate MRD and its association with prognosis in curative-intent NSCLC. World Conference on Lung Cancer 2025;Abstract P3.18.04.
- Zhou C et al. IMpower010: Biomarkers of disease-free survival in a phase 3 study of atezolizumab vs best supportive care after adjuvant chemotherapy in stage IB-IIIA NSCLC. ESMO IO 2021;Abstract 2O.
MRD analysis of adjuvant therapy with osimertinib for resected EGFR-mutated Stage IB to IIIA non-small cell lung cancer (NSCLC) (8:28)
- Herbst RS et al. Molecular residual disease analysis of adjuvant osimertinib in resected EGFR-mutated stage IB-IIIA non-small-cell lung cancer. Nat Med 2025;31(6):1958-68. Abstract
MRD analyses of perioperative chemoimmunotherapy for resected NSCLC (15:12)
- Forde PM et al. Overall survival with neoadjuvant nivolumab plus chemotherapy in lung cancer. N Engl J Med 2025;393(8):741-52. Abstract
ctDNA dynamics in advanced NSCLC treated with immunotherapy (20:56)
- Vokes NI et al. Circulating tumor DNA (ctDNA) dynamics and survival outcomes in patients (pts) with advanced non-small cell lung cancer (aNSCLC) and high (>50%) programmed cell death ligand 1 (PD-L1) expression, randomized to cemiplimab (cemi) vs chemotherapy (chemo). ASCO 2023;Abstract 9022.
- Anagnostou V et al. ctDNA response after pembrolizumab in non-small cell lung cancer: Phase 2 adaptive trial results. Nat Med 2023;29(10):2559-69. Abstract
- Anagnostou V et al. A biomarker-directed, multi-center phase II/III study of ctDNA molecular response adaptive immuno-chemotherapy in patients with non-small cell lung cancer (BR.36). ASCO 2025;Abstract TPS8669.

CME information and select publications

HR-Positive Metastatic Breast Cancer — An Interview with Dr Seth Wander on Biomarker Assessment and Related Treatment Decision-Making Apr 16, 2026

Show notes

Featuring an interview with Dr Seth Wander, including the following topics:

Deciding between liquid and tissue biopsy; role of epigenetics in oncogenic events (0:00)
Potential role of thymidine kinase testing in monitoring response to therapy (4:56)
Interpretation of next-generation sequencing testing; use of targeted therapy (10:59)
Phase III lidERA Breast Cancer trial and its implications for the use of giredestrant (14:19)
Interpreting plots from the Guardant360® test; future applications of circulating tumor DNA (19:07)
Toxicity surrounding use of agents targeting the PAM signaling pathway; treatment for patients with PAM pathway alterations and ESR1 mutations (25:15)
Potential role of artificial intelligence in profiling biomarkers; comparative efficacy of first- and later-line use of CDK inhibitors (30:26)
Case: A woman in her mid 60s diagnosed with hormone receptor (HR)-positive, HER2-low metastatic breast cancer experiences disease progression after 5 years despite letrozole/ribociclib and is found to have ESR1 mutations, treated sequentially with elacestrant then trastuzumab deruxtecan (39:10)
Case: A woman in her mid 50s who previously received treatment for localized disease develops progressive metastatic HR-positive, HER2-negative, PIK3CA-mutated breast cancer (45:31)
Case: A woman in her late 70s with HR-positive, HER2-negative breast cancer who previously received treatment for localized disease is now diagnosed with progressive PTEN-deficient metastatic disease (51:36)
Case: A woman in her early 70s with HR-positive, HER2-low metastatic breast cancer and bone metastases initially receives letrozole in combination with abemaciclib, then abemaciclib monotherapy (53:59)

CME information and select publications

HR-Positive Metastatic Breast Cancer — An Interview with Dr Seth Wander on Biomarker Assessment and Related Treatment Decision-Making (Companion Faculty Lecture) Apr 16, 2026

Show notes

Featuring a slide presentation and related discussion from Dr Seth Wander, including the following topics:

Biological impact of clinically relevant biomarkers (eg, ESR1 mutations, PIK3CA/AKT1/PTEN alterations) (0:00)
Methodologies for biomarker assessment in clinical practice: Tissue versus liquid biopsy (5:21)
Methodologies for biomarker assessment in clinical practice: Novel platforms (13:56)
Appropriate timing for assessment of ESR1 and PI3K pathway alterations (17:34)
Evolving guidelines for routine biomarker evaluation (21:37)
Implications of precision oncology clinical trials for future biomarker utility (25:07)
Summary, key questions, future directions (33:09)

CME information and select publications

Metastatic Bladder Cancer — Rapid Case Review Issue 4 Apr 15, 2026

Show notes

Featuring patient case presentations by Dr Jacqueline T Brown and Dr Nazli Dizman, with commentary from Dr Matthew Milowsky, including the following topics:

Case: A woman in her early 60s with muscle-invasive bladder cancer experiences disease progression with lung metastasis after surgery and receives enfortumab vedotin (EV)/pembrolizumab (0:00)
Case: A man in his mid 70s with metastatic urothelial bladder cancer (UBC) starts first-line EV/pembrolizumab with a partial response, and testing reveals HER2 IHC 3+ (10:58)
Case: A man in his late 60s with progression of metastatic UBC after multiple lines of therapy for whom testing reveals HER2 IHC 3+ receives trastuzumab deruxtecan (19:18)

CME information and select publications

ER-Positive, HER2-Positive Metastatic Breast Cancer — What Clinicians Want to Know About First-Line and Maintenance Therapy Apr 14, 2026

Show notes

Featuring perspectives from Dr Virginia F Borges and Dr Ian E Krop, including the following topics:

Introduction: Biology of "Triple-Positive" Breast Cancer; Implications for Therapeutic Development (0:00)
Cases from the GMO Survey (13:01)
First-Line Therapy for Metastatic HER2-Positive Disease (20:01)
Maintenance Therapy for HR-Positive, HER2-Positive Disease (30:03)
Maintenance Therapy for HR-Negative, HER2-Positive Disease (46:30)
Cases from the GMO Survey (50:00)

CME information and select publications

Localized Colorectal Cancer — Microlearning Activity 2: Proceedings from a Session Held Adjunct to the 2026 ASCO GI Cancers Symposium Apr 13, 2026

Show notes

Featuring perspectives from Dr Stacey A Cohen, Dr Christopher Lieu and Dr Jenny Seligmann, moderated by Dr Lieu, including the following topics:

Adjuvant treatment planning for Stage II or III microsatellite instability-high colon cancer (0:00)
Roles of circulating tumor DNA (ctDNA), POLE mutations and advanced age in adjuvant treatment planning (6:08)
Role of ctDNA in adjuvant treatment planning for Stage III colon cancer (12:31)

CME information and select publications

CELMoDs for Multiple Myeloma — Microlearning Activity 2 with Dr Paul G Richardson Apr 11, 2026

Show notes

Featuring perspectives from Dr Paul G Richardson, including the following topics:

EXCALIBER-RRMM: A Phase III trial of iberdomide, daratumumab and dexamethasone for relapsed/refractory multiple myeloma (0:00)
- Lonial S et al. EXCALIBER-RRMM: A phase III trial of iberdomide, daratumumab, and dexamethasone in relapsed/refractory multiple myeloma. Future Oncol 2025;21(14):1761-9. Abstract
Phase III SUCCESSOR-1 and SUCCESSOR-2 studies evaluating mezigdomide-based regimens for relapsed/refractory multiple myeloma (8:24)
- Richardson PG et al. A phase III, two-stage, randomized study of mezigdomide, bortezomib, and dexamethasone (MeziVd) versus pomalidomide, bortezomib, and dexamethasone (PVd) in relapsed/refractory multiple myeloma (RRMM): SUCCESSOR-1. SOHO 2023;Abstract MM-372.
- Richardson PG et al. A phase 3, two-stage, randomized study of mezigdomide, carfilzomib, and dexamethasone (MeziKd) versus carfilzomib and dexamethasone (Kd) in relapsed/refractory multiple myeloma (RRMM): SUCCESSOR-2. ASCO 2023;Abstract TPS8070.
EMN26: A Phase II study of maintenance therapy with iberdomide after autologous stem-cell transplantation for newly diagnosed multiple myeloma (13:34)
- van de Donk NWCJ et al. Iberdomide maintenance after autologous stem-cell transplantation in newly diagnosed multiple myeloma: An update from the phase 2 EMN26 trial. ASH 2025;Abstract 101.
STOMP: A Phase I study of selinexor, mezigdomide and dexamethasone for patients with relapsed/refractory multiple myeloma who experienced relapse with or are ineligible for T-cell-redirecting therapy (24:53)
- Mo C et al. Selinexor, mezigdomide, and dexamethasone in patients with relapsed/refractory multiple myeloma who relapsed or are ineligible for T-cell–redirecting therapy: Stomp Phase 1 results. ASH 2025;Abstract 4010.

CME information and select publications

HER2-Positive Gastrointestinal Cancers — Microlearning Activity 3: Proceedings from a Session Held Adjunct to the 2026 ASCO GI Cancers Symposium Apr 08, 2026

Show notes

Featuring perspectives from Dr Haley Ellis, Prof Eric Van Cutsem and Dr Zev Wainberg, moderated by Dr Lionel A Kankeu Fonkoua, including the following topics:

Gastroesophageal cancer (0:00)
Recurrent colorectal cancer (5:43)
Colorectal cancer with brain metastases (9:59)

CME information and select publications

Our TOPPODCAST Picks

Follow Us

Stay Connected

Research To Practice | Oncology Videos

Related Podcasts

Links

Stay Connected